Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics cash
Cash and short-term investments held at the end of each period.
Monte Rosa Therapeutics's cash was $621.10M at Jun 30, 2026. For fiscal 2025 it was $377.10M, up 64.6% from the year before. The highest annual figure on record is $377.10M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $377.10M | +64.6% |
| FY2024 | Dec 31, 2024 | $229.12M | +72.7% |
| FY2023 | Dec 31, 2023 | $132.68M | +120.4% |
| FY2022 | Dec 31, 2022 | $60.19M | -82.9% |
| FY2021 | Dec 31, 2021 | $351.41M | +719.8% |
| FY2020 | Dec 31, 2020 | $42.86M | +363.6% |
| FY2019 | Dec 31, 2019 | $9.25M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $621.10M | +113.7% |
| Q1 FY2026 | Mar 31, 2026 | $666.20M | +748.3% |
| Q4 FY2025 | Dec 31, 2025 | $377.10M | +64.6% |
| Q3 FY2025 | Sep 30, 2025 | $391.30M | +211.6% |
| Q2 FY2025 | Jun 30, 2025 | $290.60M | +167.0% |
| Q1 FY2025 | Mar 31, 2025 | $78.53M | -21.3% |
| Q4 FY2024 | Dec 31, 2024 | $229.12M | +72.7% |
| Q3 FY2024 | Sep 30, 2024 | $125.58M | +112.6% |
| Q2 FY2024 | Jun 30, 2024 | $108.85M | +131.5% |
| Q1 FY2024 | Mar 31, 2024 | $99.75M | +92.4% |
| Q4 FY2023 | Dec 31, 2023 | $132.68M | +120.4% |
| Q3 FY2023 | Sep 30, 2023 | $59.06M | -47.5% |
| Q2 FY2023 | Jun 30, 2023 | $47.03M | -54.6% |
| Q1 FY2023 | Mar 31, 2023 | $51.85M | -62.5% |
| Q4 FY2022 | Dec 31, 2022 | $60.19M | -82.9% |
| Q3 FY2022 | Sep 30, 2022 | $112.39M | -69.4% |
| Q2 FY2022 | Jun 30, 2022 | $103.66M | -71.0% |
| Q1 FY2022 | Mar 31, 2022 | $138.31M | -17.9% |
| Q4 FY2021 | Dec 31, 2021 | $351.41M | +719.8% |
| Q3 FY2021 | Sep 30, 2021 | $367.03M | +610.3% |
| Q2 FY2021 | Jun 30, 2021 | $357.06M | +2710.2% |
| Q1 FY2021 | Mar 31, 2021 | $168.44M | +1721.9% |
| Q4 FY2020 | Dec 31, 2020 | $42.86M | – |
| Q3 FY2020 | Sep 30, 2020 | $51.67M | – |
| Q2 FY2020 | Jun 30, 2020 | $12.71M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.25M | – |
See a number that looks wrong?